Überzeugende Argumente für Teva von SA-Autor Bret Jensen:
5 reasons TEVA is a strong buy at $39 a share:
Ursprünglicher Text vom 24.07.2011 :
Wenn selbst Bloomberg sagt, dass Teva steigt,...
...dann muss es wohl stimmen.
Bloomberg ist so ein Zwischending aus Nachrichtenagentur und Marktforschungsinstitut, und sie legen großen Wert darauf, weniger Falschmeldungen als alle anderen zu erzeugen. Wenn die so einen Beitrag wie diesen hier veröffentlichen, dann hat das nach meiner Erfahrung schon Substanz, und ist nicht nur eine Meinung von vielen.
Dass Teva total unterbewertet war, war schon lange klar, aber wann sie endlich steigt, ist mir erst heute klar geworden:
und deshalb ein buy
das muss jeder selber übersetzen .... ;-)
This morning, Teva Pharmaceuticals (TEVA) reported fourth quarter results. The company saw revenue of $6.5 billion and non-GAAP EPS of $1.38 for the quarter. According to YCharts, analyst consensus estimates were for revenue of $6.25 billion and EPS of $1.36. For the full year of 2016, the company reported revenue of $21.9 billion and non-GAAP EPS of $5.14. Teva also reaffirmed previous FY 2017 EPS guidance of a range of $4.90 to $5.30 per share and revenue of $23.8 billion to $24.5 billion. According to charts, analysts were looking for EPS for 2017 of $4.80 and revenue of $23.57 billion. For 2016, Teva reported an increase in revenue to $21.9 billion from $19.6 billion, a rise of nearly 12% year-over-year. Meanwhile, the cost of sales rose nearly 21% to $10.0 from $8.3 billion in 2015. That caused gross profits to increase about $500 million to $11.8 billion from $11.3 billion. Additionally, Teva's gross margins fell by about 3% to 54% in 2016 from 57% in 2015. Also, selling and marketing expenses increased to $3.8 billion from $3.5 billion, while general and administrative expenses fell to $1.236 billion in 2016 from $1.239 billion in 2015. All of the increases in costs negated any revenue gains, causing operating income to decline to $2.15 billion in 2016 from $3.35 billion in 2015. Total net income fell to $311 million in 2016 from $1.6 billion in 2015. Meanwhile, these trends on an annual basis only seemed to get worse in the fourth quarter, despite revenue rising 33% in 2016 to $6.5 billion from $4.9 billion in 2015. Meanwhile, the cost of sales soared 52% to $3.1 billion from $2.0 billion in 2015. Additionally, selling and marketing expenses also rose by 23%, to $1.1 billion from $916 million in 2015. Operating income in the fourth quarter fell from $931 million in 2015 to a loss of $137 million in the fourth quarter. Overall net income fell from $498 million in the fourth quarter of 2015 to a loss of $974 million in the current quarter. The only thing good about Teva results today is that they weren't as bad as Wall Street had feared, which is why the stock is up 4%. Preparing for life prepare for life after Copaxone and the recent resignation of CEO Erez Vigodman both have weighed on the company, and a close read of the full-year results show us Teva's recent operating problems may be getting worse, not better. (See also: Teva Shares Fall as CEO Resigns.)Read more: Teva Reports full year and fourth quarter results (TEVA) | Investopedia http://www.investopedia.com/articles/investing/021317/teva-reports-full-year-and-fourth-quarter-results-teva.asp#ixzz4YbCWTqrT Follow us: Investopedia on Facebook
Trading Teva Pharmaceutical Industries Ltd ADR
Teva Pharmaceutical Industries Ltd ADR diskutieren